As a result, BTK is a target for clinical intervention for diseases such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft-versus-host disease [3–10]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.